Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
- Once an individual becomes eligible, they remain eligible until their 80th birthday, unless they are severely immunocompromised. For this eligible cohort, there is no upper age limit.
- SHINGRIX is given according to a 2-dose vaccination schedule3,4
Shingles can place a life on hold.
Every week, patients become eligible for the Shingles National immunisation Programme.
Why wait?
Take action to help protect your patients from shingles as soon as they become eligible.
Help to reduce the burden of shingles on your patients and practice through effective implementation of the Shingles National Immunisation Programme
Shingles is a painful disease that can have serious and long-lasting complications in some patients1
Take a consistent and proactive approach to implementing the Shingles National Immunisation Programme to help protect your patients in a way that is manageable for your practice
From 1st September 2025, eligibility for shingles vaccination expands to include all severely immunocompromised individuals aged 18 and over.2,3
Visit our implementation page for links to helpful resources that support the delivery of the Shingles National Immunisation Programme
SHINGRIX helps to protect against shingles4
Prescribing information (UK)
Summary of product characteristics (UK)
References
- UK NICE Clinical Knowledge Summaries, 2024. Shingles: What are the complications?
- UK Health Security Agency. Shingles vaccination programme: expansion of Shingrix vaccine eligibility to all those who are severely immunosuppressed and aged 18 years and over. Published July 2025.
- UKHSA Green Book: Shingles (herpes zoster): the green book chapter
- SHINGRIX. Summary of Product Characteristics (UK)
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2025 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
August 2025 | PM-GB-SGX-WCNT-230004 (V8.0)
